Infusion Biosciences

What Infusion Biosciences does

Infusion Biosciences is a Toronto, Canada-based for-profit biotech company founded in 2016. Per the available firmographic metadata, the company is focused on discovering and commercializing innovative cannabis technologies, operating at a small scale with 1-10 employees. The company is privately held and Canadian-domiciled, with its corporate web presence at infusionbiosciences.com.

Beyond the high-level sector positioning and basic firmographics, substantive operational detail is largely absent from the available source material. No products or services, no proprietary technology description, no pricing model, no customer segments, no distribution channels, no marketing channels, no partnerships, no patents or trademarks, no awards, no management team, no office locations, and no M&A activity are disclosed. The company's website (infusionbiosciences.com) currently returns only a CAPTCHA/verification page rather than substantive company information, which limits direct primary-source visibility.

The only verifiable capital event in the source data is a January 2017 funding round attributed to investor Tress Capital, with the round amount listed as $0 (most plausibly an undisclosed amount). Investor quality, use of proceeds, and post-round capitalization are not described. Given the data thinness — 1-10 employees, no disclosed revenue model, no named customers, and a non-functional public-facing site — the company's current commercial stage, product status, and operational continuity cannot be reliably confirmed from the input data alone.

Name

Infusion Biosciences

Website

https://infusionbiosciences.com

Company type

Private

Founded year

2016

Headcount range

1–10 employees

Short description

Infusion Biosciences is a small, privately held Toronto-based biotech company, founded in 2016, focused on discovering and commercializing innovative cannabis technologies with a team of 1-10 employees.

Ownership category

akta.pro rank

Product category

Cannabis Biotechnology

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF)

akta.pro secondary industry

Medical Cannabis Dispensaries (CRANAFAB)

Keywords

• Cannabis biotechnology
• Biotech research
• Cannabis product development
• Life sciences R&D
• Plant science

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Core offering

Infusion Biosciences is a Canadian biotech company that discovers and commercializes innovative cannabis technologies. Operating with a small team (1-10 employees) out of Toronto, the company focuses on research, development, and downstream commercialization within the cannabis biotechnology sector.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Direct peers

• GW Pharmaceuticals: Pioneer in cannabinoid-derived prescription therapeutics (e.g., Epidiolex/nabiximols). Most directly comparable cannabis biotech in terms of discovering and commercializing cannabis-based medicines.
• Tetra Bio-Pharma: Canadian biotech developing cannabinoid-derived therapeutic products through clinical trials, sharing a similar small-cap cannabis-pharma R&D model.

Emerging players

• MediPharm Labs: Cannabis-focused company specializing in extraction and derivative manufacturing for pharmaceutical and wellness end-markets, comparable in the cannabis technology/process development niche.
• Khiron Life Sciences: Cannabis company with a clinical and medical focus, including cannabinoid-derived therapeutic and wellness products, similar in targeting medical/end-product cannabis technology.

Broad incumbents

• Canopy Growth Corporation: Large Canadian cannabis company with significant R&D and IP development, broadly competing in the cannabis technology and therapeutics space.
• Tilray Brands: Major global cannabis company with a pharma division developing cannabinoid-based medicines, representing a well-capitalized incumbent in the same category.
• Jazz Pharmaceuticals: Acquired GW Pharmaceuticals in 2021, becoming a major commercializer of cannabis-derived therapies; relevant as a potential strategic acquirer and benchmark for the cannabis-pharma thesis.
• Aphria (now part of Tilray): Large Canadian licensed producer with a focus on medical cannabis and cannabinoid-based product development, broadly comparable in the medical cannabis technology space.
• OrganiGram Holdings: Canadian licensed producer investing in cannabis R&D and derivative products, sharing exposure to the Canadian cannabis technology ecosystem.
• Cronos Group: Globally diversified cannabis company with biotechnology-style R&D partnerships (e.g., with Ginkgo Bioworks), representing a comparable large-scale cannabis biotech platform play.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks4 records

Key highlights3 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Infusion Biosciences